

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date:	February 2009 April 19,2011, June 18,2012, November 23, 2015

XIFAXAN® (rifaximin)

LENGTH OF AUTHORIZATION: Varies per indication

Review Criteria:

- Diarrhea caused by *E. Coli* – length of approval: 3 days
 - Patient must be \geq 12 years of age.
 - Patient must **not** be experiencing fevers and/or bloody stools.
 - Patient must have a documented culture indicating causative microorganism is *E. Coli*.

- Hepatic Encephalopathy- length of approval up to 6 months
 - Patient must be \geq 18 years of age.
 - Patient must have a confirmed (from medical records or diagnosis codes) diagnosis of hepatic encephalopathy.
 - Patient must be currently taking or have had a documented trial of lactulose.

- Irritable Bowel Syndrome (refractory)-length of approval up to 6 weeks.
 - Patient must be \geq 18 years of age.
 - Patient must have a diagnosis of Irritable Bowel Syndrome (IBS) with diarrhea as the predominant symptom, confirmed with colonoscopic examination within the previous 2 years. (*A copy of the colonoscopy results should be submitted or addressed in the MD progress notes.*)
 - Patient must have had a documented trial of 3 of the treatment options listed below since the diagnosis of IBS:
 1. Lifestyle and dietary modifications
 - Elimination of caffeine, lactose or fructose from diet **and/or**
 - Addition of fiber to diet **and/or**
 - Use of Probiotics
 2. Antidiarrheals (i.e. loperamide, cholestyramine)
 3. Antispasmodics (i.e. dicyclomine, hyoscyamine)
 4. Tricyclic antidepressants (i.e. desipramine, amitriptyline, doxepin)

Dosing:

- Recommended dose for the treatment of traveler’s diarrhea: 200 mg three times daily for 3 days.
- Recommended dose for the treatment of hepatic encephalopathy: 550 mg twice daily.
- Recommended dose for the treatment of IBS: 550 mg three times daily for 14 days. Dose may be repeated up to two additional times (maximum of three total treatment cycles).